Organic anion transporting polypeptides (OATPs), encoded by SLC21 / SLCO genes, are essential influx transporters responsible for the cellular uptake of diverse endogenous molecules and clinical drugs 1 , 2 , 3 . The OATP family comprises six subfamilies with distinct tissue distribution and substrate specificity, among which liver-enriched OATP1B1/1B3 and widely distributed OATP2B1 are the most pharmacologically critical isoforms 4 . Unlike OATP1B1/1B3 that primarily mediate hepatic drug clearance, OATP2B1 regulates both intestinal drug absorption and hepatic extraction, serving as a key mediator of food–drug and drug–drug interactions (DDIs) 5 , 6 . Accumulating evidence indicates that OATP2B1 inhibition contributes to unexplained alterations in systemic drug exposure beyond OATP1B1/1B3 modulation, highlighting its unique pharmacological importance 7 . Moreover, genetic variations in SLCO2B1 alter drug transport efficiency, leading to interindividual differences in drug response and adverse drug reactions 8 , 9 . Despite its functional significance, the lack of high-resolution structural information of OATP2B1 has hindered the mechanistic understanding of its substrate recognition, specificity, and conformational transport dynamics.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: